A study published in The Journal of the National Cancer Institute, found that advanced chemotherapy put patients at far greater
risks of harm than adverse effect reports from clinical trial data reveal.
Suicide rates fluctuate. Like the stock market their rise and fall is not due to a single decisive cause, but rather to a confluence of complex factors.
An editorial in today's New York Times is a follow-up to its riveting report by Ian Urbina on the recommendation by an Institute of Medicine panel to
lift 1978 federal restrictions on medical experiments on prisoners. http://www.nytimes.com/2006/08/13/us/13inmates.html?
A Boston Globe report (below) focuses on three recent reports in the Journal of the American Medical Association (JAMA) by Harvard researchers who violated the journal’s disclosure policy by failing to disclose their financial ties to companies that had the most to gain from their purported findings.
"Even though clinical research is a noble and worthy activity, it’s very easy to lose your moral compass if your primary goal is the dollar amount of grant funding that you generate."
Steven Potkin, who, LAT reports, is a brother-in-law of Jane Pauley who wrapped up her career as TV news anchor to become a paid drug pusher.
The law firm of Baum Hedlund filed a lawsuit against GlaxoSmithKline, the maker of the antidepressant, Paxil, for causing severe heart defects in the newborn son, of a woman prescribed Paxil during her pregnancy.
Today’s New York Times editorial hits the mark–it’s right on target!
The Associated Press reports (1, 2 below) that the FDA has just issued new warnings about two additional life-threatening risks induced by SSRI antidepressants: Serotonin Syndrome and Persistent Pulmonary Hypertension in newborn babies.
The Wall Street Journal and Bloomberg News report about a case involving Neuropsychopharmacology, the official journal of the American College of Neuropsychopharmacology (ACNP) that will likely go down in history as psychiatry’s Watergate.
Operating like thieves under the cover of darkness, prominent academic-based "authorities" in medical specialties have debased academic standards and sold their reputations for cash-
The latest investigative report focusing on financial conflicts of interest by Pulitzer Prize winner, David Willman of the Los Angeles Times, reveals that even as the NIH director, Dr. Elias Zerhouni, announced publicly last year that scientists at the National Institutes of Health would be barred from accepting consulting fees from industry, evidence shows that the ban is clearly not being enforced.
